eGenesis

Thesis

eGenesis (Cambridge, MA) received FDA IND clearance for its Phase I/II/III study of EGEN-2784 (September 2025). Patient Tim Andrews received a pig kidney in January 2025 and has surpassed seven months post-transplant. The longest-living pig organ recipient, dialysis-free. Patient Bill Stewart received a kidney in June 2025 and completed a two-hour bike ride. The EGEN-2784 pig has 69 gene edits. 3 xeno-antigen knockouts, 7 human transgene insertions, 59 PERV inactivations. Total funding is $454-481M from Lux Capital, ARCH Ventures, Khosla Ventures, Leaps by Bayer, DaVita, and 32+ institutions. Available on EquityZen/Forge for accredited investors. This is one of the most medically significant frontier technologies in this report. 100,000+ Americans are on the organ transplant waitlist, and 17 die daily waiting. If pig-to-human transplantation achieves FDA approval, the addressable market is enormous and the human impact is transformative. The FDA IND clearance is a critical regulatory milestone. This is now in formal clinical trials, not just compassionate use. The seven-month survival of Tim Andrews without dialysis is the strongest clinical signal in xenotransplantation history.

Catalysts

• +FDA IND cleared for Phase I/II/III study of EGEN-2784. In formal clinical trials
• +Tim Andrews surpassed 7 months post-transplant dialysis-free. Longest pig organ recipient
• +$454-481M funding from Lux Capital, ARCH, Khosla, Leaps by Bayer, DaVita

Risks

• -Organ rejection at scale remains the fundamental biological risk
• -Regulatory path beyond IND clearance is long. Full FDA approval could take years
• -Private company. Accredited investor access only via EquityZen/Forge

Common questions